1. Home
  2. DYN vs OMDA Comparison

DYN vs OMDA Comparison

Compare DYN & OMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DYN
  • OMDA
  • Stock Information
  • Founded
  • DYN 1984
  • OMDA 2011
  • Country
  • DYN United States
  • OMDA United States
  • Employees
  • DYN N/A
  • OMDA N/A
  • Industry
  • DYN Medicinal Chemicals and Botanical Products
  • OMDA Medical/Nursing Services
  • Sector
  • DYN Health Care
  • OMDA Health Care
  • Exchange
  • DYN Nasdaq
  • OMDA Nasdaq
  • Market Cap
  • DYN 1.2B
  • OMDA 1.3B
  • IPO Year
  • DYN 2020
  • OMDA 2025
  • Fundamental
  • Price
  • DYN $9.38
  • OMDA $19.25
  • Analyst Decision
  • DYN Strong Buy
  • OMDA Strong Buy
  • Analyst Count
  • DYN 15
  • OMDA 6
  • Target Price
  • DYN $43.07
  • OMDA $24.17
  • AVG Volume (30 Days)
  • DYN 3.3M
  • OMDA 577.2K
  • Earning Date
  • DYN 08-11-2025
  • OMDA 08-07-2025
  • Dividend Yield
  • DYN N/A
  • OMDA N/A
  • EPS Growth
  • DYN N/A
  • OMDA N/A
  • EPS
  • DYN N/A
  • OMDA N/A
  • Revenue
  • DYN N/A
  • OMDA $189,668,000.00
  • Revenue This Year
  • DYN N/A
  • OMDA $33.26
  • Revenue Next Year
  • DYN N/A
  • OMDA $20.16
  • P/E Ratio
  • DYN N/A
  • OMDA N/A
  • Revenue Growth
  • DYN N/A
  • OMDA 38.29
  • 52 Week Low
  • DYN $6.36
  • OMDA $14.14
  • 52 Week High
  • DYN $47.45
  • OMDA $28.40
  • Technical
  • Relative Strength Index (RSI)
  • DYN 45.89
  • OMDA N/A
  • Support Level
  • DYN $8.95
  • OMDA N/A
  • Resistance Level
  • DYN $9.83
  • OMDA N/A
  • Average True Range (ATR)
  • DYN 0.55
  • OMDA 0.00
  • MACD
  • DYN 0.17
  • OMDA 0.00
  • Stochastic Oscillator
  • DYN 74.58
  • OMDA 0.00

About DYN Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Share on Social Networks: